Cargando…

Comparison of the rapidity of SARS-CoV-2 immune responses between primary and booster vaccination for COVID-19

BACKGROUND/AIMS: The rapidity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific memory B or T cell response in vaccinated individuals is important for our understanding of immunopathogenesis of coronavirus disease 2019 (COVID-19). We therefore compared the timing of adequate i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ji Yeun, Kwon, Ji-Soo, Cha, Hye Hee, Lim, So Yun, Bae, Seongman, Kim, Sung-Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association of Internal Medicine 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666257/
https://www.ncbi.nlm.nih.gov/pubmed/36217813
http://dx.doi.org/10.3904/kjim.2022.173
_version_ 1784831463812759552
author Kim, Ji Yeun
Kwon, Ji-Soo
Cha, Hye Hee
Lim, So Yun
Bae, Seongman
Kim, Sung-Han
author_facet Kim, Ji Yeun
Kwon, Ji-Soo
Cha, Hye Hee
Lim, So Yun
Bae, Seongman
Kim, Sung-Han
author_sort Kim, Ji Yeun
collection PubMed
description BACKGROUND/AIMS: The rapidity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific memory B or T cell response in vaccinated individuals is important for our understanding of immunopathogenesis of coronavirus disease 2019 (COVID-19). We therefore compared the timing of adequate immune responses between the first and booster doses of COVID-19 vaccines in infection-naïve healthcare workers. METHODS: We enrolled healthcare workers who received two doses of either the BNT162b2 vaccine or the ChAdOx1 vaccine, all of whom received the BNT162b2 vaccine as the booster (the third) dose. Spike 1 (S1)-immunoglobulin G (IgG) antibodies and interferon gamma producing T cell responses were measured at 0, 7, 14, and 21 days after the first dose, and at 0 and between 2 to 7 days after the booster dose. RESULTS: After the first-dose vaccination, the S1-IgG antibody responses were elicited within 14 days in the BNT162b2 group and within 21 days in the ChAdOx1 group. After the booster dose, the S1-IgG antibody responses were elicited within 5 days in both groups. The SARS-CoV-2-specific T cell responses appeared at 7 days after the first dose and at 4 days after the booster dose. CONCLUSIONS: SARS-CoV-2-specific immune responses by memory B cells and T cells may be expected to appear around 4 to 5 days after the booster dose.
format Online
Article
Text
id pubmed-9666257
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Korean Association of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-96662572022-11-28 Comparison of the rapidity of SARS-CoV-2 immune responses between primary and booster vaccination for COVID-19 Kim, Ji Yeun Kwon, Ji-Soo Cha, Hye Hee Lim, So Yun Bae, Seongman Kim, Sung-Han Korean J Intern Med Original Article BACKGROUND/AIMS: The rapidity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific memory B or T cell response in vaccinated individuals is important for our understanding of immunopathogenesis of coronavirus disease 2019 (COVID-19). We therefore compared the timing of adequate immune responses between the first and booster doses of COVID-19 vaccines in infection-naïve healthcare workers. METHODS: We enrolled healthcare workers who received two doses of either the BNT162b2 vaccine or the ChAdOx1 vaccine, all of whom received the BNT162b2 vaccine as the booster (the third) dose. Spike 1 (S1)-immunoglobulin G (IgG) antibodies and interferon gamma producing T cell responses were measured at 0, 7, 14, and 21 days after the first dose, and at 0 and between 2 to 7 days after the booster dose. RESULTS: After the first-dose vaccination, the S1-IgG antibody responses were elicited within 14 days in the BNT162b2 group and within 21 days in the ChAdOx1 group. After the booster dose, the S1-IgG antibody responses were elicited within 5 days in both groups. The SARS-CoV-2-specific T cell responses appeared at 7 days after the first dose and at 4 days after the booster dose. CONCLUSIONS: SARS-CoV-2-specific immune responses by memory B cells and T cells may be expected to appear around 4 to 5 days after the booster dose. Korean Association of Internal Medicine 2022-11 2022-10-11 /pmc/articles/PMC9666257/ /pubmed/36217813 http://dx.doi.org/10.3904/kjim.2022.173 Text en Copyright © 2022 The Korean Association of Internal Medicine https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Ji Yeun
Kwon, Ji-Soo
Cha, Hye Hee
Lim, So Yun
Bae, Seongman
Kim, Sung-Han
Comparison of the rapidity of SARS-CoV-2 immune responses between primary and booster vaccination for COVID-19
title Comparison of the rapidity of SARS-CoV-2 immune responses between primary and booster vaccination for COVID-19
title_full Comparison of the rapidity of SARS-CoV-2 immune responses between primary and booster vaccination for COVID-19
title_fullStr Comparison of the rapidity of SARS-CoV-2 immune responses between primary and booster vaccination for COVID-19
title_full_unstemmed Comparison of the rapidity of SARS-CoV-2 immune responses between primary and booster vaccination for COVID-19
title_short Comparison of the rapidity of SARS-CoV-2 immune responses between primary and booster vaccination for COVID-19
title_sort comparison of the rapidity of sars-cov-2 immune responses between primary and booster vaccination for covid-19
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666257/
https://www.ncbi.nlm.nih.gov/pubmed/36217813
http://dx.doi.org/10.3904/kjim.2022.173
work_keys_str_mv AT kimjiyeun comparisonoftherapidityofsarscov2immuneresponsesbetweenprimaryandboostervaccinationforcovid19
AT kwonjisoo comparisonoftherapidityofsarscov2immuneresponsesbetweenprimaryandboostervaccinationforcovid19
AT chahyehee comparisonoftherapidityofsarscov2immuneresponsesbetweenprimaryandboostervaccinationforcovid19
AT limsoyun comparisonoftherapidityofsarscov2immuneresponsesbetweenprimaryandboostervaccinationforcovid19
AT baeseongman comparisonoftherapidityofsarscov2immuneresponsesbetweenprimaryandboostervaccinationforcovid19
AT kimsunghan comparisonoftherapidityofsarscov2immuneresponsesbetweenprimaryandboostervaccinationforcovid19